The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Ranolazine 750 mg Prolonged-release tablet

Elc Group s.r.o.PA23245/003/003

Main Information

Trade NameRanolazine 750 mg Prolonged-release tablet
Active SubstancesRanolazine
Dosage FormProlonged-release tablet
Licence HolderElc Group s.r.o.
Licence NumberPA23245/003/003

Group Information

ATC CodeC01EB18 ranolazine


License statusAuthorised
Licence Issued29/07/2022
Legal status*** AWAITING VALUE ***
Supply Status
Advertising Status*** AWAITING VALUE ***
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back